Dr Claire Foldi, left, and Dr Kyra Conn
Characterised by pathological weight loss driven by restrictive feeding and excessive exercise behaviours, anorexia nervosa (AN) has one of the highest mortality rates of any psychiatric disease.
Some small clinical trials have shown that psilocybin, the active ingredient in magic mushrooms, may be a potential treatment for anorexia nervosa. The condition is characterised by cognitive inflexibility, or rigid thinking and there is evidence that psilocybin acts to increase this flexibility.
However – crucial to the use of the drug as a recognised treatment for anorexia – is the need to understand how psilocybin actually works in the brain. Now, a study led by Dr Claire Foldi from the Monash University Biomedicine Discovery Institute and published in the journal Molecular Psychiatry, has studied psilocybin in an animal model of anorexia nervosa – revealing that it
improves body weight maintenance in female rats and facilitates cognitive flexibility.
Importantly, the Monash researchers found a specific mechanism within the brain by which psilocybin works to make "anorexic thinking" more pliable, opening the way for targeted therapies.
According to Dr Foldi, while selective serotonin reuptake inhibitors (antidepressants) are the leading pharmacological treatment, they are used off-label and "they do not improve clinical symptoms in underweight individuals with anorexia," she said.
"Cognitive inflexibility is a hallmark of the condition often arising before symptoms of anorexia nervosa are obvious, and persisting after weight recovery – making this symptom a primary target for therapeutic intervention."
Read the full paper in Molecular Psychiatry: Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms.
DOI: 10.1038/s41380-024-02575-9
About the Monash Biomedicine Discovery Institute
Committed to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
